Narrow search
Showing 1 - 10 of 18
Cover Image
Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007
Conti, Rena M.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2014
estimated prices of these drug undergoing LOE fall with generic entry. Second, we estimate reduced form random effects models of … utilization subsequent to LOE. We observe substantial price erosion after generic entry; average monthly price declines appear to … entry, but this result appears to be largely driven by oral drugs. We discuss second-best welfare consequences of these …
Persistent link: https://www.econbiz.de/10010950850
Cover Image
The Effect of FDA Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts
Conti, Rena M.; Huskamp, Haiden A.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2011
The US Food and Drug Administration (FDA) expends considerable efforts in regulating medications approved for use. Yet the impact of medication labeling changes on brand pharmaceutical products, and whether and what firms do to respond to increased information regarding the safety and efficacy...
Persistent link: https://www.econbiz.de/10009325511
Cover Image
Pricing and Reimbursement in U.S. Pharmaceutical Markets
Berndt, Ernst R.; Newhouse, Joseph P. - National Bureau of Economic Research (NBER) - 2010
comment on very recent developments concerning the entry of large retailers such as Wal-Mart into domains traditionally …
Persistent link: https://www.econbiz.de/10008531891
Cover Image
Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation
Berndt, Ernst R.; Aitken, Murray L. - National Bureau of Economic Research (NBER) - 2010
following initial generic entry and by 24 months to 65, in 2009 the comparable generic price indexes are 68 and 27, respectively … patent has expired. Across all nine therapeutic areas, at 24 months post-generic entry, the weighted mean reduction in …
Persistent link: https://www.econbiz.de/10008682661
Cover Image
Costs, Institutional Mobility Barriers, and Market Structure: Advertising Agencies as Multiproduct Firms
Silk, Alvin J.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 1994
low fixed costs and minimal entry barriers, both media-specific scale and scope economies are available and can be …
Persistent link: https://www.econbiz.de/10005248932
Cover Image
Effects of Pharmaceutical Promotion: A Review and Assessment
Dave, Dhaval M. - National Bureau of Economic Research (NBER) - 2013
and prices is more limited. However, there is no strong evidence that drug promotion deters entry, and there is some …
Persistent link: https://www.econbiz.de/10010950788
Cover Image
Does Medicaid Coverage for Pregnant Women Affect Prenatal Health Behaviors?
Dave, Dhaval M.; Kaestner, Robert; Wehby, George L. - National Bureau of Economic Research (NBER) - 2015
Despite plausible mechanisms, little research has evaluated potential changes in health behaviors as a result of the Medicaid expansions of the 1980s and 1990s for pregnant women. Accordingly, we provide the first national study of the effects of Medicaid on health behaviors for pregnant women....
Persistent link: https://www.econbiz.de/10011213646
Cover Image
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
Philipson, Tomas; Berndt, Ernst R.; Gottschalk, Adrian H. B. - National Bureau of Economic Research (NBER) - 2004
Congress enacted and renewed the Prescription Drug User Fee Acts (PDUFA) in 1992, and renewed it in 1997 and 2002, mandating FDA performance goals in reviewing and acting on drug applications within specified time periods. In turn, the FDA was permitted to levy user fees on drug sponsors...
Persistent link: https://www.econbiz.de/10005084928
Cover Image
Demand for Illicit Drugs by Pregnant Women
Dave, Dhaval M.; Corman, Hope; Noonan, Kelly; Reichman, … - National Bureau of Economic Research (NBER) - 2004
We use survey data that have been linked to medical records data and city-level drug prices to estimate the demand for illicit drugs among pregnant women. The prevalence of prenatal drug use based on post partum interviews was much lower than that based on evidence in the mothers' and babies'...
Persistent link: https://www.econbiz.de/10005019411
Cover Image
The Impact of Direct-to-Consumer Advertising on Pharmaceutical Prices and Demand
Dave, Dhaval M.; Saffer, Henry - National Bureau of Economic Research (NBER) - 2010
Expenditures on prescription drugs are one of the fastest growing components of national health care spending, rising by almost three-fold between 1995 and 2007. Coinciding with this growth in prescription drug expenditures has been a rapid rise in direct-to-consumer advertising (DTCA), made...
Persistent link: https://www.econbiz.de/10008628364